Aprea Therapeutics reported a net loss of $3.0 million, or $0.47 per share, for the third quarter ended September 30 2025, compared with a $3.8 million loss and $0.59 per share in the same quarter last year. Operating loss was $3.1 million, down from $4.1 million in Q3 2024, reflecting a $1.2 million reduction in research and development spending that fell to $1.6 million from $2.8 million. General and administrative costs were $1.5 million, unchanged from the prior year. Cash and cash equivalents stood at $13.7 million, giving the company a runway to fund operations through the fourth quarter of 2026.
The cash balance, while sufficient for the stated runway, triggers a 10‑month going‑concern warning in the company’s latest 10‑Q filing, indicating that additional financing will likely be required to sustain long‑term development activities.
In the phase I/II ACESOT‑1051 study of the WEE1 inhibitor APR‑1051, three of four patients in the 100 mg once‑daily cohort achieved stable disease, and the study has progressed to the 150 mg cohort. The data cutoff was October 19 2025, and the early anti‑tumor activity supports the planned dose escalation and informs the design of the upcoming phase II expansion.
The ATR inhibitor ATRN‑119 entered the ABOYA‑119 trial with a recommended phase 2 dose of 1,100 mg once daily. Enrollment in the monotherapy arm has been paused to evaluate combination strategies with radiation or checkpoint inhibitors, a shift that reflects the company’s focus on synergistic approaches to enhance clinical benefit.
CEO Oren Gilad said the company is pleased with the progress in both programs, noting that the emerging data demonstrate evidence of activity and reinforce the company’s DNA damage response (DDR) strategy. He emphasized the importance of the early clinical signals for future development and the potential to address unmet needs in oncology.
Analysts and investors have focused on the clinical milestones and liquidity position as key drivers of market sentiment. The early activity in APR‑1051 and the identification of a phase 2 dose for ATRN‑119 provide tangible evidence of the pipeline’s potential, while the cash runway to Q4 2026 offers a buffer against the inherent financial risks of a clinical‑stage company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.